A kind of isotretinoin crystalline product and preparation method thereof
Through the combination of Cu target Kα ray and differential thermal analysis technology, the solubility and purity problems in the preparation of isotretinoic acid are solved, and the high purity and stability of isotretinoic acid crystalline products are achieved, and the preparation stability and product are improved. Practical value.
Patent Information
- Application Number
- CN202411076544.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-08-07
AI Technical Summary
During the preparation process of the existing isotretinoic acid, due to the solubility of the solubility and the preparation process are not rigorous, the crystal purity of isotretinoic acid is insufficient, the impurities grow rapidly, and the stable state cannot be maintained, and efficient and reasonable preparation cannot be carried out.
By using powder X-ray powder diffraction pattern and differential thermal analysis pattern of Cu target Kα rays, combined with the preparation control system to perform steps such as heating dissolution, crystallization and filtration, to ensure the solubility and crystallization conditions of the crude isotretinoic acid solution, and achieve the High purity and stability of isotretinoic acid crystalline products.
It effectively guarantees the purity and stability of isotretinoic acid crystalline products, reduces potential problems in the preparation process, and improves the preparation stability and practical value of the product.
Smart Images

Figure CN118580169B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of crystalline product preparation, in particular to an isotretinoin crystalline product and a preparation method thereof. Background Art
[0002] At present, in the preparation process of isotretinoin, due to the problems of isotretinoin solubility not meeting the standard and the lax preparation process, the purity of the isotretinoin crystals obtained is insufficient, and the impurities of the obtained isotretinoin crystals increase rapidly under air conditions. Isotretinoin cannot be maintained in a stable state, and cannot be prepared efficiently and reasonably.
[0003] For example, the invention patent with announcement number CN113214126B is a method for preparing vitamin A acetate, which comprises: C15 phosphonate and C5 aldehyde undergo addition reaction in the presence of alkaline compounds to generate an ylide; the ylide undergoes decomposition reaction to obtain the vitamin A acetate; during the reaction, the content of the ylide in the reaction system is ≤0.06 mol / L. The preparation method is based on the Witting reaction of C15+C5, and by controlling the content of the ylide in the reaction system during the reaction, vitamin A acetate with high purity, high trans-isomer selectivity and high yield is obtained. The preparation method is suitable for reactions of any scale, and can be carried out in batches, semi-continuously or completely continuously. The obtained vitamin A acetate has low chromaticity, good antioxidant properties and thermal stability, low deterioration rate, is conducive to long-term stable storage, and has good market competitiveness.
[0004] For example, the invention patent with announcement number CN114031534B is a high-stability vitamin A and its preparation method. In the method, a C15 phosphonate mixture and a five-carbon aldehyde are subjected to a Witting reaction under the action of an alkali solution to prepare a crude vitamin A acetate oil, and then the vitamin A crystals are obtained by recrystallization. By controlling the content of compound I and compound II in the C15 phosphonate mixture to 0.1wt%-1wt%, the VA dimer content in the crude vitamin A acetate oil is less than 0.1%, which can significantly improve the chemical stability of the vitamin A product. The chromaticity value of the obtained VA crystal solution is less than 60HAzen, and the average size of the VA crystals is 100-200μm, which effectively solves the problems of yellowing color, easy agglomeration, and large particle size of the VA crystals.
[0005] In combination with the above technical solutions, it is found that in the current preparation process, on the one hand, there is a lack of analysis of compound dissolution, and it is impossible to accurately understand the dissolution of the compound in the early stage; on the other hand, the purity of the final crystalline product has not been inspected, resulting in the crystalline product may not meet the purity standard, and the stable production status of the crystalline product cannot be guaranteed, and the maintenance cost of the preparation process is additionally increased. Summary of the invention
[0006] In view of the deficiencies in the prior art, the present invention provides an isotretinoin crystalline product and a preparation method thereof, which can effectively solve the problems involved in the above-mentioned background technology.
[0007] To achieve the above objectives, the present invention is implemented through the following technical solutions: In a first aspect, the present invention provides a crystalline isotretinoin product, comprising using Cu target Kα rays, and its powder X-ray powder diffraction pattern has characteristic peaks at 5.74±0.2, 10.45±0.2, 11.48±0.2, 11.92±0.2, 12.62±0.2, 15.94±0.2, 16.43±0.2, 16.67±0.2, 16.70±0.2, 18.07±0.2, 18.34±0.2, 19.69±0.2, 20.21±0.2, 21.75±0.27, 23.95±0.27, 24.70±0.27, 25.37±0.27, 26.97±0.27 and 27.56±0.2.
[0008] Furthermore, the DSC spectrum of the crystalline isotretinoin preparation has an endothermic peak at 183.0±2°C.
[0009] The second aspect of the present invention provides a method for preparing an isotretinoin crystalline product, comprising:
[0010] S1. Heating and dissolving: Under nitrogen protection, weigh the initial weight of crude isotretinoin into a container, add a certain volume of ethyl acetate, heat to a specified temperature to dissolve, and start stirring;
[0011] S2. Preparation control determination: After stirring, data processing is performed to obtain the solubility corresponding to the crude isotretinoin solution to be prepared. When the solubility corresponding to the crude isotretinoin solution to be prepared determined by the preparation control system is higher than the solubility of the solution corresponding to the set specific temperature, the preparation control system controls the temperature control device to reduce the crude isotretinoin solution to a preset temperature;
[0012] S3. Preparation of isotretinoin crystalline product: Control the crystallization equipment through the preparation control system so that the crystallization time of the crude isotretinoin solution is the preset crystallization time, control the filtration equipment so that the filtration times of the crude isotretinoin solution is the preset filtration times, and vacuum dry the obtained filter cake at a specified temperature controlled by the preparation control system to obtain the isotretinoin crystalline product.
[0013] As a further method, the solvent for the crystallization is preferably ethyl acetate, and the amount of ethyl acetate used is 10-20 ml / g based on the weight of the crude product, wherein the preferred solvent amount of ethyl acetate is 10-15 ml / g.
[0014] As a further method, the preparation control system comprises:
[0015] The temperature rise dissolution determination module is used to dissolve the isotretinoin crude product to be prepared in ethyl acetate and perform a temperature rise operation to determine the solubility corresponding to the isotretinoin crude product solution to be prepared. If the solubility corresponding to the isotretinoin crude product solution to be prepared is higher than the solubility of the solution corresponding to the set specific temperature, the preparation control evaluation module is executed, and the isotretinoin crude product solution to be prepared is recorded as an isotretinoin preparable crude product solution. Otherwise, the temperature rise dissolution determination module is continued to be executed; the preparation control evaluation module is used to analyze the preparation control evaluation of the isotretinoin preparable crude product solution by performing a preparation operation on the isotretinoin preparable crude product solution. An estimation factor is obtained, and the crystalline product in the crude product solution of isotretinoin that can be prepared after the preparation operation is recorded as the isotretinoin crystalline product, and the purity limit value of the isotretinoin crystalline product is obtained by matching; a stable state evaluation module is used to comprehensively analyze the X-ray powder diffraction pattern of the isotretinoin crystalline product, the differential thermal analysis pattern of the isotretinoin crystalline product, and the 5,6-epoxyisotretinoin content of the isotretinoin crystalline product during the air exposure period according to the purity limit value of the isotretinoin crystalline product, to obtain the preparation stability evaluation index of the isotretinoin crystalline product, and to evaluate the preparation stability of the isotretinoin crystalline product.
[0016] Compared with the prior art, the embodiments of the present invention have at least the following advantages or beneficial effects:
[0017] (1) The present invention provides an isotretinoin crystalline product and a preparation method thereof. The method first determines the solubility corresponding to the isotretinoin crude solution to be prepared, and can clearly obtain the dissolution of the isotretinoin crude solution. Secondly, the preparation of the isotretinoin crude solution is controlled, and the preparation process of the isotretinoin crude solution can be analyzed in detail, providing data basis for the final evaluation of the stability of the isotretinoin crystalline product.
[0018] (2) The present invention dissolves the crude isotretinoin to be prepared in ethyl acetate and performs a temperature increase operation to determine whether the solubility of the crude isotretinoin solution to be prepared is higher than the solubility of the solution corresponding to a set specific temperature, thereby timely adjusting the dissolution of the crude isotretinoin solution to ensure that the solubility of the crude isotretinoin solution meets the corresponding standard, thereby providing a more sufficient preparation basis for the subsequent preparation process of the crude isotretinoin solution.
[0019] (3) The present invention performs a preparation operation on a preparable crude solution of isotretinoin, wherein the preparation operation process includes cooling, crystallization, filtration and drying, and comprehensively analyzes the preparation control evaluation factors of the preparable crude solution of isotretinoin, thereby providing comprehensive data support for matching the purity limit value of the isotretinoin crystalline product, and helping to timely discover potential problems in the preparation process of the preparable crude solution of isotretinoin, so that timely countermeasures can be taken to ensure the purity of the finally obtained isotretinoin crystalline product.
[0020] (4) The present invention can evaluate the preparation stability of the isotretinoin crystalline product based on the purity of the isotretinoin crystalline product, the X-ray powder diffraction pattern of the isotretinoin crystalline product, and the differential thermal analysis pattern of the isotretinoin crystalline product. At the same time, the content of 5,6-epoxyisotretinoin in the isotretinoin crystalline product during the air exposure period can be used to understand the impurity content of the isotretinoin crystalline product prepared by the present invention when exposed to the air. The preparation process can be adjusted and managed in time according to the impurity growth rate of the isotretinoin crystalline product to improve the preparation stability of the isotretinoin crystalline product, and at the same time, it is beneficial for the isotretinoin crystalline product to show practical value. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] The present invention is further described using the accompanying drawings, but the embodiments in the accompanying drawings do not constitute any limitation to the present invention. A person skilled in the art can obtain other drawings based on the following drawings without creative work.
[0022] Figure 1 It is a schematic diagram of the method steps of the present invention;
[0023] Figure 2 It is a schematic diagram of system module connection of the present invention;
[0024] Figure 3 It is a schematic diagram of the change of the dissolution temperature index of the crude isotretinoin solution to be prepared according to the present invention;
[0025] Figure 4 The X-ray powder diffraction pattern of the isotretinoin crystalline product involved in the present invention;
[0026] Figure 5 This is a differential thermal analysis spectrum of the isotretinoin crystalline product involved in the present invention.
[0027] Figure numerals: 1, heating dissolution straight line segment. DETAILED DESCRIPTION
[0028] The technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0029] The first aspect of the present invention provides a crystalline isotretinoin product, comprising: using Cu target Kα rays, its powder X-ray powder diffraction pattern has characteristic peaks at 5.74±0.2, 10.45±0.2, 11.48±0.2, 11.92±0.2, 12.62±0.2, 15.94±0.2, 16.43±0.2, 16.67±0.2, 16.70±0.2, 18.07±0.2, 18.34±0.2, 19.69±0.2, 20.21±0.2, 21.75±0.27, 23.95±0.27, 24.70±0.27, 25.37±0.27, 26.97±0.27 and 27.56±0.2.
[0030] Furthermore, the DSC spectrum of the isotretinoin crystalline preparation has an endothermic peak at 183.0±2°C.
[0031] Reference Figure 1 As shown, the second aspect of the present invention provides a method for preparing a crystalline isotretinoin product, comprising: S1. heating and dissolving: under nitrogen protection, weighing an initial weight of crude isotretinoin into a three-necked flask of an initial volume, adding a certain volume of ethyl acetate, heating to a specified temperature for dissolution, and starting stirring; S2. preparation control determination: after stirring, performing data processing to obtain the solubility corresponding to the crude isotretinoin solution to be prepared, when the solubility corresponding to the crude isotretinoin solution to be prepared determined by the preparation control system is higher than the solubility of the solution corresponding to the set specific temperature, the preparation control system controls the temperature regulating device to reduce the crude isotretinoin solution to a preset temperature; S3. preparation of crystalline isotretinoin product: controlling the crystallization device through the preparation control system so that the crystallization time of the crude isotretinoin solution is the preset crystallization time, controlling the filtering device so that the number of filtrations of the crude isotretinoin solution is the preset number of filtrations, and vacuum drying the obtained filter cake at a specified temperature controlled by the preparation control system to obtain the crystalline isotretinoin product.
[0032] It should be explained that the above-mentioned initial weight is 10g, and the initial volume is 500ml, wherein the certain volume of ethyl acetate ranges from 100ml to 150ml; the specified temperature ranges from 65±5°C, and its specific temperature value may vary due to changes in influencing factors such as the temperature difference between the initial surface temperature of the crude isotretinoin and the initial temperature of ethyl acetate, and the initial weight of the crude isotretinoin; the setting of the specific temperature is the same as the setting condition of the specified temperature, that is, it may vary due to changes in influencing factors such as the temperature difference between the initial surface temperature of the crude isotretinoin and the initial temperature of ethyl acetate, and the initial weight of the crude isotretinoin. However, in this example, if the temperature is raised to the specified temperature of 60°C, the specific temperature may be set to 50°C, because the heating operation is completed before the stirring of the crude isotretinoin solution begins, and there will be a certain degree of The temperature is lowered, so if the solubility of the crude isotretinoin solution to be prepared is higher than the solubility of the solution corresponding to the set 50°C, the next step of cooling can be carried out; the specific temperature range is 55±5°C; the preset temperature range is -5±5°C; the specified temperature value is 50°C, and the preset crystallization time may vary due to factors such as the temperature difference between the specified temperature and the preset temperature, the addition of additional crystals during the crystallization process, etc., but in this example, the preset crystallization time is set to 10 hours, and the preset number of filtrations is adjusted accordingly according to the above preset temperatures. In this example, if the preset temperature is -5°C, the preset number of filtrations is set to 10 times; the purpose of stirring in this example is to help disperse the isotretinoin particles so that they are more evenly distributed in ethyl acetate, avoid precipitation or stratification, and ensure the uniformity of the mixture.
[0033] In this exemplary embodiment, the above preparation method has four specific embodiments, and the preparation process is as follows:
[0034] Example 1: Under nitrogen protection, weigh 10g of crude isotretinoin into a 500ml three-necked flask, add 100mL of ethyl acetate, start stirring, heat to 65±5°C to dissolve, cool to -5±5°C to crystallize for 10 hours, and filter. The filter cake is vacuum dried at 50°C to obtain 8.58g of isotretinoin A crystal form, with a mass yield of 85.8% and a purity of 99.89%.
[0035] Example 2: Under nitrogen protection, weigh 10 g of crude isotretinoin into a 500 ml three-necked flask, add 120 ml of ethyl acetate, start stirring, heat to 65±5°C to dissolve, cool to -5±5°C to crystallize for 10 hours, and filter. The filter cake is vacuum dried at 50°C to obtain 8.37 g of isotretinoin A crystal form, with a mass yield of 83.7% and a purity of 99.88%.
[0036] Example 3: Under nitrogen protection, weigh 10 g of crude isotretinoin into a 500 ml three-necked flask, add 150 ml of ethyl acetate, start stirring, heat to 65±5°C to dissolve, cool to -5±5°C to crystallize for 10 hours, and filter. The filter cake is vacuum dried at 50°C to obtain 8.06 g of isotretinoin A crystal form, with a mass yield of 80.6% and a purity of 99.86%.
[0037] Example 4: Under nitrogen protection, weigh 10 g of crude isotretinoin into a 500 ml three-necked flask, add 150 ml of ethyl acetate, start stirring, heat to 65±5°C to dissolve, cool to -5±5°C to crystallize for 10 hours, and filter. The filter cake is vacuum dried at 50°C to obtain 8.06 g of isotretinoin A crystal form, with a mass yield of 80.6% and a purity of 99.86%.
[0038] It should be explained that, according to the above four embodiments, it can be concluded that by adding different volumes of ethyl acetate, the weight, mass yield and purity of the isotretinoin crystalline product finally obtained are different. It is known that the volume capacity of ethyl acetate will have a great influence on the preparation control of the isotretinoin crystalline product. Therefore, in the process of preparing the isotretinoin crystalline product, not only the preparation process should be considered, but also the influence of the volume of ethyl acetate should be considered to ensure that the purity of the isotretinoin crystalline product finally obtained is always higher than its purity limit value, thereby ensuring the stability of the isotretinoin crystalline product.
[0039] Furthermore, after the isotretinoin crystalline product is exposed to air for 10 days, the content of 5,6-epoxyisotretinoin is less than 0.05%.
[0040] It should be explained that after the above-mentioned isotretinoin crystalline product was exposed to air for 10 days, the impurity 5,6-epoxyisotretinoin contained only 0.05%, indicating that the preparation method of the isotretinoin crystalline product in this example can effectively inhibit the oxidation of the isotretinoin crystalline product, improve the stability of the isotretinoin crystalline product, and ultimately the isotretinoin crystalline product has a higher practical value.
[0041] Specifically, the crystallization solvent is preferably ethyl acetate. Calculated by the weight of the crude product, the amount of ethyl acetate is 10-20 ml / g, wherein the preferred solvent amount of ethyl acetate is 10-15 ml / g. By optimizing the solvent amount, the isotretinoin crystalline product can obtain better purity, and its crystal quality and yield can be improved.
[0042] Example 5: A method for preparing a crystalline isotretinoin product, wherein the preparation control system is referenced Figure 2 As shown, including:
[0043] The temperature rise dissolution determination module is used to dissolve the crude isotretinoin to be prepared in ethyl acetate and perform a temperature rise operation to determine the solubility corresponding to the crude isotretinoin solution to be prepared. If it is higher than the solubility of the solution corresponding to the set specific temperature, the preparation control evaluation module is executed, and the crude isotretinoin solution to be prepared is recorded as an isotretinoin preparable crude solution. Otherwise, the temperature rise dissolution determination module is continued to be executed.
[0044] The preparation control evaluation module is used to analyze the preparation control evaluation factors of the preparable crude isotretinoin solution by performing preparation operations on the preparable crude isotretinoin solution, and record the crystalline product in the preparable crude isotretinoin solution after the preparation operation as the isotretinoin crystalline product, and match it to obtain the purity limit value of the isotretinoin crystalline product.
[0045] The stable state evaluation module is used to obtain the preparation stability evaluation index of the isotretinoin crystalline product according to the purity limit value of the isotretinoin crystalline product, and to conduct a comprehensive analysis of the X-ray powder diffraction pattern of the isotretinoin crystalline product, the differential thermal analysis pattern of the isotretinoin crystalline product, and the 5,6-epoxyisotretinoin content of the isotretinoin crystalline product during the air exposure period, and to evaluate the preparation stability state of the isotretinoin crystalline product.
[0046] Specifically, the preparation control system also includes a crystal preparation control library, which is used to store the cooling limit time, crystallization time threshold, crystallization limit yield, filtration reference times, filter cake allowable quality and filter cake porosity limit value, and the first straight line of airflow adaptation speed.
[0047] In this embodiment, the values in the above-mentioned crystal preparation control library are fitted based on statistical multiple historical preparation data. For example, the crystallization time threshold is obtained by obtaining the crystallization time of multiple isotretinoin crystalline products through different crystallization preparation processes of multiple isotretinoin crystalline products, and the preparation management personnel determine whether the purity of the isotretinoin crystalline products under each crystallization time meets the required standards. The crystallization times corresponding to the purity of the isotretinoin crystalline products that meet the required standards are averaged and used as the crystallization time threshold. In this way, the values in the crystal preparation control library are obtained, and the values therein will be adjusted with the changes in the crystal type and preparation process, and this embodiment does not make any special limitation on this.
[0048] The temperature rise dissolution determination module is connected to the preparation control evaluation module, the preparation control evaluation module is connected to the stable state evaluation module, and the preparation control evaluation module is connected to the crystal preparation control library.
[0049] The temperature rise dissolution determination module is used to dissolve the crude isotretinoin to be prepared in ethyl acetate and perform a temperature rise operation to determine the solubility corresponding to the crude isotretinoin solution to be prepared. If the solubility corresponding to the crude isotretinoin solution to be prepared is higher than the solubility of the solution corresponding to the set specific temperature, the preparation control evaluation module is executed, and the crude isotretinoin solution to be prepared is recorded as an isotretinoin preparable crude solution. On the contrary, if the solubility corresponding to the crude isotretinoin solution to be prepared is lower than or equal to the set minimum solubility, the temperature rise dissolution determination module continues to be executed.
[0050] Specifically, the solubility of the crude isotretinoin solution to be prepared is determined by:
[0051] The crude isotretinoin to be prepared is dissolved in ethyl acetate, and the volume corresponding to the ethyl acetate is obtained therefrom, which can be obtained from the measured value of the volume meter.
[0052] According to the temperature increase operation, the crude isotretinoin solution to be prepared is randomly arranged as various temperature increase collection points to obtain the temperature value of each temperature increase collection point at each dissolution time point, and the temperature value is obtained by a temperature sensor.
[0053] It should be explained that the above-mentioned dissolution time points are obtained by obtaining the dissolution cycle through statistical analysis based on factors such as the weight of the crude isotretinoin and the volume of ethyl acetate, and the dissolution cycle is divided into dissolution time points of equal length.
[0054] The set dissolution temperature reference value is comprehensively analyzed and processed through a polynomial regression model to obtain the dissolution temperature index corresponding to each dissolution time point.
[0055] It should be explained that the above-mentioned dissolution temperature reference value is determined by statistical analysis based on historical dissolution data, such as dissolution volume, dissolution time and other factors, and represents the best adaptation value of the dissolution temperature.
[0056] In this embodiment, the process of obtaining the dissolution temperature index corresponding to each dissolution time point is as follows:
[0057] First, the temperature values of each heating collection point at different dissolution time points and the set dissolution temperature reference value are collected to establish a data set; an appropriate linear polynomial regression model is selected, the temperature value is used as the dependent variable, the dissolution time point and the set dissolution temperature reference value are used as independent variables, and the model is fitted by minimizing the residual sum of squares to find the best fitting polynomial function; the fitted polynomial regression model is evaluated, including checking whether the residual conforms to the normal distribution and the fit of the model; each dissolution time point is predicted using the fitted polynomial regression model to obtain the dissolution temperature index corresponding to each dissolution time point.
[0058] Construct a dissolution temperature index change curve of the crude isotretinoin solution to be prepared, such as Figure 3 As shown, the horizontal axis of the dissolution temperature index change line is the dissolution time point, and the unit is piece; the vertical axis is the temperature dissolution index, and the unit is percentage.
[0059] Locate the connecting straight line between the dissolution temperature index corresponding to the starting dissolution time point and the dissolution temperature index corresponding to the ending dissolution time point, and record the slope corresponding to the connecting straight line as the dissolution temperature slope of the crude isotretinoin solution to be prepared.
[0060] In this embodiment, the dissolution temperature slope of the crude isotretinoin solution to be prepared is specifically as follows:
[0061] According to the dissolution temperature index change curve of the crude isotretinoin solution to be prepared, Figure 3 As shown, the dissolution temperature index corresponding to the starting dissolution time point and the dissolution temperature index corresponding to the ending dissolution time point are located, and the straight-line distance is measured. The obtained straight line is recorded as the temperature-increasing dissolution straight line segment 1 of the crude isotretinoin solution to be prepared, and the dissolution temperature slope of the crude isotretinoin solution to be prepared is obtained by slope calculation.
[0062] In this embodiment, through the dissolution temperature index change curve of the crude isotretinoin solution to be prepared, it is obtained that the temperature of the crude isotretinoin solution to be prepared is constantly rising during the heating operation, but it is not a linear rise, indicating that when the crude isotretinoin in the crude isotretinoin solution to be prepared is dissolved, the state of the crude isotretinoin solution to be prepared changes slowly over time, and the dissolution temperature slope is analyzed to understand whether the temperature change state of the crude isotretinoin solution to be prepared is reasonable, so as to adjust the preparation process in time.
[0063] The solubility of the crude isotretinoin solution to be prepared is determined thereby. In another embodiment, deep learning technology can be used to process large-scale and complex chemical data of the crude isotretinoin solution to predict the solubility of the crude isotretinoin solution.
[0064] In this embodiment, the solubility corresponding to the crude isotretinoin solution to be prepared can be integrated and analyzed by the volume corresponding to ethyl acetate and the dissolution temperature slope of the crude isotretinoin solution to be prepared to obtain a value for the solubility of the crude isotretinoin solution. A more accurate algorithm is as follows:
[0065]
[0066] In the formula, is the solubility corresponding to the crude isotretinoin solution to be prepared. In this embodiment, if the volume of ethyl acetate is too large, the temperature gradient of the crude isotretinoin solution may be more gentle during the heating operation, which is not conducive to the continuous and stable temperature rise of the crude isotretinoin solution, so the slope in the temperature curve will be more stable; but if the volume of ethyl acetate is too small, the heating operation time of the crude isotretinoin dissolved in ethyl acetate is too long, which will cause the important compounds in the crude isotretinoin solution to evaporate, and finally the purity of the crude isotretinoin solution and the quality of the crystalline product will be reduced; and the relationship between the above-mentioned influencing factors and solubility can be more accurately expressed in a more compact way, providing a clearer and more comprehensive data basis for the final data acquisition.
[0067] is the correction factor corresponding to the volume, It is the influencing factor of the unit value corresponding to the dissolution temperature slope, where the correction factor corresponding to the volume and the influencing factor corresponding to the unit value of the dissolution temperature slope can be obtained through the influencing factors in the historical dissolution report and according to the statistical method; the correction factor corresponding to the volume represents the degree of correction corresponding to the volume change, and its value range is 0 to 0.5. In this example, the value is specified as 0.25; the influencing factor of the unit value corresponding to the dissolution temperature slope represents the degree of influence of the change of the dissolution temperature slope, and its value range is 0.1 to 0.51. In this example, the value is specified as 0.5.
[0068] V is the volume corresponding to ethyl acetate, which refers to the capacity of ethyl acetate, and the unit is usually milliliters.
[0069] The volume adaptation amount is calculated based on the molar ratio of ethyl acetate in the chemical reaction equation, and represents the adaptation value of the ethyl acetate addition capacity. In this embodiment, the volume adaptation amount value is set to 120 ml.
[0070] k is the dissolution temperature slope of the crude isotretinoin solution to be prepared, which refers to the slope value in the dissolution temperature index change line.
[0071] In this embodiment, the solubility values of the crude isotretinoin solution to be prepared are shown in Table 1:
[0072] Table 1 Solubility of crude isotretinoin solution to be prepared
[0073] Volume / mL Melting temperature slope / % Solubility 100 57 5.81 110 100 30.56 150 100 4.43
[0074] In this exemplary embodiment, according to the table of solubility corresponding to the crude isotretinoin solution to be prepared, the closer the volume corresponding to ethyl acetate is to the volume adaptation amount, the larger the solubility value is, indicating that the solubility of the crude isotretinoin solution to be prepared is higher; at the same time, as the dissolution temperature slope is larger and the volume corresponding to ethyl acetate deviates from the volume adaptation amount, the solubility value is smaller; in summary, to ensure that the value of the solubility corresponding to the crude isotretinoin solution to be prepared is larger, the difference between the volume corresponding to ethyl acetate and the volume adaptation amount needs to be smaller, while ensuring that the dissolution temperature slope is within a reasonable range.
[0075] In a specific embodiment, the present invention dissolves the crude isotretinoin to be prepared in ethyl acetate and performs a temperature increase operation to obtain whether the solubility corresponding to the crude isotretinoin solution to be prepared is higher than the solubility of the solution corresponding to a set specific temperature, and thus timely adjusts the dissolution of the crude isotretinoin solution to ensure that the solubility of the crude isotretinoin solution meets the corresponding standard, thereby providing a more sufficient preparation basis for the subsequent preparation process of the crude isotretinoin solution.
[0076] The preparation control evaluation module is used to analyze the preparation control evaluation factors of the preparable crude isotretinoin solution by performing preparation operations on the preparable crude isotretinoin solution, and record the crystalline product in the preparable crude isotretinoin solution after the preparation operation as the isotretinoin crystalline product, and match it to obtain the purity limit value of the isotretinoin crystalline product.
[0077] In this embodiment, the above-mentioned crude solution of isotretinoin can be prepared by the following preparation steps:
[0078] The crude isotretinoin is dissolved in ethyl acetate, heated to dissolve, then cooled to a specified temperature, crystallized and filtered, and the filter cake is transferred to a vacuum drying device to finally obtain isotretinoin.
[0079] Specifically, the preparation operation is performed on the isotretinoin crude solution to obtain the cooling execution set, crystallization execution set, filtration execution set and drying execution set of the isotretinoin crude solution.
[0080] Furthermore, the preparation operation is performed on the crude solution of isotretinoin to obtain the cooling execution set, crystallization execution set, filtration execution set and drying execution set of the crude solution of isotretinoin, wherein the cooling execution set includes the cooling time, which is specifically obtained by monitoring the cooling time through a timer.
[0081] The crystallization execution set includes the crystallization time, the crystallization temperature difference and the crystallization quality.
[0082] It should be explained that the above-mentioned crystallization time can be obtained according to a timer; the crystallization quality is obtained by a quality sensor, wherein the crystallization temperature difference represents the temperatures of the crude solution of isotretinoin that can be prepared during the crystallization process, which can be obtained by a temperature sensor, and finally the difference between the maximum temperature value and the minimum temperature value is processed to obtain the crystallization temperature difference.
[0083] The filtering execution set includes the number of filtrations, the mass of the filter cake corresponding to each filtration, and the maximum porosity of the filter cake.
[0084] It should be explained that the above-mentioned filtration times can be obtained through the steps determined in advance in the experimental operation process; the mass of the filter cake is usually obtained by calculating the mass difference before and after weighing the filter membrane; the maximum porosity of the filter cake can be calculated by measuring the mass and net weight of the filter cake according to the specific gravity method.
[0085] The drying execution set includes the average drying temperature of the isotretinoin preparable crude solution during the drying cycle and the gas pressure of the vacuum drying equipment at each drying time point.
[0086] It should be explained that the average drying temperature of the crude isotretinoin solution during the drying cycle can be obtained by a temperature sensor at each time point during the drying cycle, and the average drying temperature during the drying cycle is obtained by summing up the temperature; wherein the drying cycle refers to the time period of the crude isotretinoin solution in the vacuum drying equipment; the gas pressure of the vacuum drying equipment at each drying time point can be obtained by a pressure sensor to obtain the pressure value of the vacuum drying equipment, wherein each drying time point is obtained by randomly dividing the drying cycle.
[0087] Specifically, the matching obtains the purity limit value of the isotretinoin crystalline product, and the specific matching process is:
[0088] The crystalline product in the preparable crude solution of isotretinoin in the preparation operation is recorded as the isotretinoin crystalline product, and the preparation control evaluation factor of the preparable crude solution of isotretinoin is matched with the purity limit value corresponding to each preparation control evaluation factor interval to obtain the purity limit value of the isotretinoin crystalline product.
[0089] In this embodiment, the purity limit values corresponding to the above-mentioned preparation control evaluation factor intervals can be obtained by searching the purity data and related information under the preparation conditions of the specific compound to comprehensively obtain the purity limit values corresponding to the preparation control evaluation factor intervals.
[0090] It should be explained that the purity limit value of the crude solution of isotretinoin can be prepared as described above, and the matching process is as follows:
[0091] First, it is necessary to determine the key control evaluation factors that affect the preparation of crude isotretinoin solution. These factors may include reaction temperature, reaction time, raw material ratio, solvent selection, reaction pressure, etc.; collect corresponding purity data under various preparation conditions through literature research channels; use existing data and experimental results to establish the association between preparation control evaluation factors and purity; according to the established association model, match the control evaluation factors used in the actual preparation with the purity data in the corresponding interval, so that the purity limit value of the preparation of crude isotretinoin solution can be inferred.
[0092] Furthermore, the preparation control evaluation factors of the crude solution of isotretinoin can be prepared by analyzing the specific analysis process as follows:
[0093] The mass of the obtained isotretinoin crystalline product is compared with the mass of the isotretinoin crude solution that can be prepared, and the mass yield of the isotretinoin crystalline product is obtained.
[0094] It should be explained that the quality of the above-mentioned isotretinoin crystalline product can be obtained from the measurement data of the quality sensor.
[0095] In this embodiment, the preparation control evaluation factors of the above-mentioned isotretinoin can be prepared into a crude solution. In another embodiment, the linear relationship of multiple control evaluation factors affecting the preparation of isotretinoin can be analyzed according to a multivariate linear regression model, and the preparation control evaluation factors of the isotretinoin can be prepared into a crude solution can be obtained by fitting the experimental data.
[0096] According to the mass yield of the isotretinoin crystalline product, the first control evaluation index of isotretinoin that can be used to prepare a crude solution, the second control evaluation index of isotretinoin that can be used to prepare a crude solution, the third control evaluation index of isotretinoin that can be used to prepare a crude solution, and the fourth control evaluation index of isotretinoin that can be used to prepare a crude solution are comprehensively processed to obtain the preparation control evaluation factor of isotretinoin that can be used to prepare a crude solution, and the formula is as follows:
[0097]
[0098] In the formula, is a preparation control evaluation factor of a crude solution of isotretinoin that can be prepared. In this embodiment, the cooling process of the crude solution of isotretinoin that can be prepared can promote the crystallization process in the crude solution of isotretinoin that can be prepared; and according to the crystallization process of the crude solution of isotretinoin that can be prepared, if the conditions such as the crystallization time and the crystallization temperature are kept within a reasonable range, it is beneficial to increase the filtration time of the crystals to improve the purity of the crystals; at the same time, through the filtration process of the crude solution of isotretinoin that can be prepared, impurities and solvents in the solution are removed, providing more accurate conditions for the subsequent drying process, and also improving the purity of the crystals; and an appropriate drying process can improve the stability and mass yield of the crystals; conversely, if the final mass yield of the crystals is not high, it means that there will be unreasonable processes in the crude preparation process, and timely maintenance and adjustment are required to improve the purity and stability of the crystals.
[0099] It is the first control evaluation index for the preparation of crude solution of isotretinoin. It is the second control evaluation index for the preparation of crude solution of isotretinoin. It is the third control evaluation index for the preparation of crude solution of isotretinoin. It is the fourth control evaluation index for the preparation of crude solution of isotretinoin.
[0100] The mass-defined yield can be obtained by analyzing historical mass yield data and is the minimum mass yield of the crystal.
[0101] M is the mass yield of the isotretinoin crystalline product, which is the mass of the crystals divided by the mass of the crude product, indicating the quality of the final prepared crystals.
[0102] The correction value of the preparation control evaluation factor is obtained by analyzing the historical preparation data. It represents the correction degree of the change of the preparation control evaluation factor. Its value range is 0.49 to 0.58. In this example, the value is specified as 0.5.
[0103] e is a natural constant.
[0104] Specifically, the preparation control evaluation factors of the crude solution of isotretinoin can be prepared, and the specific data analysis process is as follows:
[0105] The cooling execution set of the crude solution of isotretinoin that can be prepared is analyzed and processed by an autoregressive integrated moving average model to obtain a first control evaluation index of the crude solution of isotretinoin that can be prepared.
[0106] It should be explained that the analysis and processing process of the first control evaluation index of the above-mentioned isotretinoin that can be prepared as a crude solution is as follows:
[0107] First, the time series data related to the cooling preparation of the crude solution of isotretinoin are collected, including the cooling time and the cooling limit time defined in the crystal preparation control library; the order of the autoregressive integrated moving average model is determined by observing the autocorrelation function and partial autocorrelation function graph of the data; the determined autoregressive integrated moving average model order is used to fit the data, and the parameters of the model are estimated; the fitted model is diagnosed to test whether the residual sequence meets the characteristics of the white noise sequence; the fitted autoregressive integrated moving average model is used to predict the data to obtain the first control evaluation index of the crude solution of isotretinoin.
[0108] The crystallization execution set of the isotretinoin crude solution is analyzed and processed by the principal component analysis model to obtain the second control evaluation index of the isotretinoin crude solution.
[0109] It should be explained that the analysis process of the second control evaluation index of the above-mentioned crude solution of isotretinoin is as follows:
[0110] The crystallization time of the crude solution of isotretinoin that can be prepared is compared with the crystallization time threshold stored in the crystal preparation control library to obtain the crystallization time influencing factor of the crude solution of isotretinoin that can be prepared.
[0111] The crystallization mass of the isotretinoin preparable crude solution is compared with the mass of the obtained isotretinoin preparable crude solution to obtain the crystallization yield of the isotretinoin preparable crude solution, wherein the mass of the isotretinoin preparable crude solution is obtained by a mass sensor.
[0112] The crystallization yield of the crude solution that can be prepared according to isotretinoin is multiplied by the crystallization limit yield stored in the crystal preparation control library to obtain the crystallization yield influencing factor of the crude solution that can be prepared by isotretinoin.
[0113] The crystallization temperature difference of the crude solution of isotretinoin that can be prepared is compared with the crystallization temperature limit difference preset in the crystal preparation control library to obtain the crystallization temperature difference ratio of the crude solution of isotretinoin that can be prepared.
[0114] The second control evaluation index of the isotretinoin crude solution that can be prepared by preparing the crude product solution is obtained by adding the influencing factor of the crystallization time, the crystallization temperature difference ratio and the crystallization yield influencing factor of the isotretinoin crude solution.
[0115] The filtered execution set of the isotretinoin crude solution is analyzed and processed by a multiple regression analysis model to obtain a third control evaluation index of the isotretinoin crude solution.
[0116] It should be explained that the analysis process of the third control evaluation index of the above-mentioned isotretinoin for preparing the crude solution is as follows:
[0117] According to the filtration times of isotretinoin for preparing crude solution, the mass of filter cake corresponding to each filtration, and the maximum porosity of filter cake, the third control evaluation index of isotretinoin for preparing crude solution is obtained by comparing with the reference filtration times, the allowable mass of filter cake and the limit value of filter cake porosity defined in the crystal preparation control library, and through the multivariate regression analysis model analysis and processing.
[0118] It should be explained that the third control evaluation index of the crude solution of isotretinoin can be prepared, and the acquisition process is as follows:
[0119] Collect variable data such as filtration times, filter cake quality, filter cake porosity, and reference values defined in the crystal preparation control library; establish a multiple regression model, in which filtration times, filter cake quality, filter cake porosity, etc. are used as independent variables, and reference values defined in the crystal preparation control library are used as dependent variables, and explore the relationship between them through regression analysis; fit the established multiple regression model and estimate the model parameters; diagnose the fitted multiple regression model to test whether the residuals meet the model assumptions and evaluate the fitting effect of the model; use the fitted multiple regression model to make predictions and obtain the third control evaluation index for the preparation of crude solution of isotretinoin.
[0120] The drying execution set of the isotretinoin preparable crude solution is analyzed and processed by a neural network model to obtain a fourth control evaluation index of the isotretinoin preparable crude solution.
[0121] It should be explained that the analysis process of the fourth control evaluation index of the above-mentioned isotretinoin that can be used to prepare a crude solution is as follows:
[0122] The average drying temperature of the isotretinoin preparable crude solution during the drying cycle is compared with the drying adaptation temperature preset in the crystal preparation control library to obtain the temperature influence ratio of the isotretinoin preparable crude solution during the drying cycle; the gas pressure of the vacuum drying equipment at each drying time point is compared with the atmospheric standard pressure preset in the crystal preparation control library, and the vacuum degree of the vacuum drying equipment during the drying cycle is obtained by averaging.
[0123] The fourth control evaluation index of the isotretinoin preparable crude solution is obtained by adding the temperature influence ratio of the isotretinoin preparable crude solution during the drying cycle and the vacuum degree of the vacuum drying equipment during the drying cycle.
[0124] In a specific embodiment, the present invention performs a preparation operation on a preparable crude solution of isotretinoin, wherein the preparation operation process includes cooling, crystallization, filtration and drying, and comprehensively analyzes the preparation control evaluation factors of the preparable crude solution of isotretinoin, thereby providing comprehensive data support for matching the purity limit value of the isotretinoin crystalline product, and facilitating timely discovery of potential problems in the preparation process of the preparable crude solution of isotretinoin, so that timely countermeasures can be taken to ensure the purity of the finally obtained isotretinoin crystalline product.
[0125] The stable state evaluation module is used to obtain the preparation stability evaluation index of the isotretinoin crystalline product based on the purity limit value of the isotretinoin crystalline product and the obtained X-ray powder diffraction spectrum of the isotretinoin crystalline product and the differential thermal analysis spectrum of the isotretinoin crystalline product, and evaluate the preparation stability state of the isotretinoin crystalline product.
[0126] Specifically, the preparation stability of the isotretinoin crystalline product is evaluated, and the specific evaluation process is:
[0127] The preparation stability assessment index of isotretinoin crystalline product is compared with the set preparation stability assessment threshold, wherein the preparation stability assessment threshold is statistically obtained from the historical stable preparation data of the crystal, indicating the minimum qualified value of the preparation stability assessment index.
[0128] If the preparation stability assessment index of the isotretinoin crystalline product is higher than the set preparation stability assessment threshold, preparation stability feedback is performed on the preparation stability state of the isotretinoin crystalline product, and the feedback process is as follows:
[0129] According to the situation that the preparation stability assessment index of the isotretinoin crystalline product exceeds the preparation stability assessment threshold, it can be obtained that the preparation stability assessment index of the isotretinoin crystalline product has reached the stability standard of the isotretinoin crystalline product, and it is only necessary to feed back the preparation stability assessment index and other parameters of the isotretinoin crystalline product obtained by the algorithm to the preparation information platform. The preparation information platform automatically evaluates the preparation stability assessment index and other parameters of the isotretinoin crystalline product. After determining that it meets the set standards, the preparation process, preparation information, etc. of this experiment are stored in the crystal preparation control library as reference information for subsequent experiments; the above-mentioned preparation information platform represents an information platform for recording the preparation process of isotretinoin, which is constructed when the crude isotretinoin to be prepared is dissolved in ethyl acetate. By recording the preparation process in detail, not only can problems in the preparation be discovered in a timely manner, but also detailed data basis can be provided for subsequent preparation processes.
[0130] If the preparation stability assessment index of the isotretinoin crystalline product is equal to or lower than the set preparation stability assessment threshold, a preparation alarm prompt is issued for the preparation stability state of the isotretinoin crystalline product, and the alarm prompt process is as follows:
[0131] According to the situation that the preparation stability assessment index of the isotretinoin crystalline product is equal to or lower than the preparation stability assessment threshold, it can be obtained that the preparation stability assessment index of the isotretinoin crystalline product has not reached the stability standard of the isotretinoin crystalline product. The preparation information platform can automatically generate an alarm prompt according to the situation that the preparation stability assessment index of the isotretinoin crystalline product is equal to or lower than the preparation stability assessment threshold, reminding the relevant operators that there is a risk in the stability of the isotretinoin crystalline product. The relevant operators can find the preparation problems, such as aging of the preparation equipment, by searching the preparation information recorded in the preparation information platform, and take corresponding solutions, such as improving the equipment performance of the preparation process, increasing or decreasing the solvent volume, and changing the value of the specified temperature (in this example, when the value of the specified temperature is changed, the specified temperature is still maintained at 65±5℃ The reason is that ethyl acetate is an organic solvent. Even though it can dissolve isotretinoin, its solubility is not infinite. At a specified temperature, isotretinoin can reach its maximum solubility in ethyl acetate. Beyond this temperature range, the solubility may decrease, resulting in excess solid precipitation or the formation of a turbid solution. Therefore, the temperature needs to be controlled to maintain the dissolution equilibrium. At the same time, the heating process will affect the interaction between the two, such as hydrogen bonds, van der Waals forces, etc. If the temperature is too high, these forces will be destroyed, which will not only affect the mixing effect, but also cause the subsequent crystallized isotretinoin to be unstable), the set value of the specific temperature (due to the change of the above-mentioned specified temperature, the specific temperature will change accordingly), etc.; it is beneficial to avoid the above-mentioned problems when isotretinoin is prepared again in the future, so as to obtain a stable isotretinoin crystalline product.
[0132] Furthermore, the preparation stability evaluation index of the isotretinoin crystalline product is specifically analyzed as follows:
[0133] It should be explained that, in another embodiment, the preparation stability evaluation index of the above-mentioned isotretinoin crystalline product can also be described by a Bayesian network with the probabilistic dependency relationship between the variables of the isotretinoin crystalline product, and probabilistic inference and prediction can be performed to obtain the preparation stability evaluation index.
[0134] The X-ray powder diffraction pattern of the isotretinoin crystalline product is obtained according to the X-ray diffraction technique, by using Cu target Kα rays, and expressing the X-ray powder diffraction pattern of the isotretinoin crystalline product at 2θ angles, such as Figure 4As shown, the abscissa is the diffraction angle, the unit is degree, and the ordinate is the diffraction intensity, the unit is count; it is found that there are characteristic peaks at 5.74±0.2, 10.45±0.2, 11.48±0.2, 11.92±0.2, 12.62±0.2, 15.94±0.2, 16.43±0.2, 16.67±0.2, 16.70±0.2, 18.07±0.2, 18.34±0.2, 19.69±0.2, 20.21±0.2, 21.75±0.27, 23.95±0.27, 24.70±0.27, 25.37±0.27, 26.97±0.27 and 27.56±0.2.
[0135] In this embodiment, the powder state of the isotretinoin crystalline product can be known in detail through the X-ray powder diffraction pattern, and the image data basis can be provided for the subsequent determination of the stability of the isotretinoin crystalline product by analyzing the number of characteristic peaks and the diffraction angle corresponding to the horizontal axis; by observing the peak shape and peak width in the X-ray powder diffraction pattern, the quality and purity of the isotretinoin crystalline product can be evaluated. If the quality of the isotretinoin crystalline product is not high or there are too many impurities, the peaks in the X-ray powder diffraction pattern will become wider or additional peaks will appear, thereby affecting the stability of the isotretinoin crystalline product; in short, the X-ray powder diffraction pattern is a commonly used material analysis technology. By analyzing the parameters such as the position, intensity, shape and width of the peaks in the X-ray powder diffraction pattern, the crystal structure, lattice parameters, relative content, quality and purity of the isotretinoin crystalline product can be determined, and this information is of great significance for the research and application in the field of materials science and engineering.
[0136] The characteristic peak position number of the isotretinoin crystalline product is extracted therefrom. In this embodiment, the characteristic peak position number is 19.
[0137] In this way, the peak width and diffraction intensity corresponding to each characteristic peak position of the isotretinoin crystalline product are obtained.
[0138] It should be explained that the peak width corresponding to the above-mentioned characteristic peak positions refers to the peak width corresponding to each characteristic peak in the X-ray powder diffraction spectrum, and the peak width and diffraction intensity can be directly extracted from the X-ray powder diffraction spectrum.
[0139] By processing the peak width and diffraction intensity corresponding to each characteristic peak position of the isotretinoin crystalline product, the characteristic peak influence of the isotretinoin crystalline product in the X-ray powder diffraction pattern can be obtained.
[0140] It should be explained that the specific processing process of the characteristic peak influence of the above-mentioned isotretinoin crystalline product in the X-ray powder diffraction spectrum is as follows:
[0141] The peak width corresponding to each characteristic peak position of the isotretinoin crystalline product is multiplied by the influence factor corresponding to the unit peak width preset in the crystal preparation control library to obtain the peak width influence index corresponding to each characteristic peak position of the isotretinoin crystalline product; the diffraction intensity corresponding to each characteristic peak position of the isotretinoin crystalline product is multiplied by the influence factor corresponding to the unit diffraction intensity preset in the crystal preparation control library to obtain the diffraction intensity influence index corresponding to each characteristic peak position of the isotretinoin crystalline product, and the peak width influence index corresponding to each characteristic peak position of the isotretinoin crystalline product is added to obtain the characteristic peak influence index corresponding to each characteristic peak position of the isotretinoin crystalline product, and the indexes are arranged in descending order to extract the characteristic peak influence index ranked first, which is recorded as the characteristic peak influence degree of the isotretinoin crystalline product in the X-ray powder diffraction pattern.
[0142] According to the differential thermal analysis spectrum of the isotretinoin crystalline product, it is obtained by differential scanning calorimetry analysis, such as Figure 5 As shown, the horizontal axis is temperature, the unit is degree, and the vertical axis is heat flow, the unit is milliwatt; from the figure, it can be seen that there is an endothermic peak at 183.0±2℃.
[0143] In this embodiment, through the differential thermal analysis spectrum, the position of the endothermic peak of the isotretinoin crystalline product and the corresponding heat flow can be known according to the image. Through the heat flow of the isotretinoin crystalline product, the thermal reaction of the isotretinoin crystalline product can be clearly obtained, and the stability of the isotretinoin crystalline product can be provided in more detail.
[0144] The heat flow corresponding to the endothermic peak position of the isotretinoin crystalline product is located and extracted.
[0145] The purity of the isotretinoin crystalline product is obtained, wherein the purity is determined by evaluating the thermal properties of the isotretinoin crystalline product by differential scanning calorimetry and taking into account the preparation process of the crystals.
[0146] With regard to the 5,6-epoxyisotretinoin content of the comprehensive isotretinoin crystalline preparation during the air exposure period, it should be explained that the above-mentioned 5,6-epoxyisotretinoin content can be determined by a high performance liquid chromatography instrument, wherein the air exposure period in this example refers to the time that the isotretinoin crystalline preparation is exposed to the air, and the unit is day.
[0147] In this embodiment, a more accurate algorithm for evaluating the preparation stability of the above-mentioned isotretinoin crystalline product is as follows:
[0148]
[0149] In the formula, It represents the preparation stability evaluation index of the isotretinoin crystalline product. In this embodiment, for the isotretinoin crystalline product, its X-ray powder diffraction pattern reflects the orderliness and crystal quality of the crystal. If there is an impurity in the crystal, that is, the content of 5,6-epoxyisotretinoin is large, the purity of the isotretinoin crystalline product is not high, and the X-ray powder diffraction pattern may show additional diffraction peaks or peak broadening, and the corresponding diffraction intensity is not within a reasonable range; if the X-ray powder diffraction pattern shows impurities or structural defects, it may cause additional heat absorption or heat release peaks to appear in the differential thermal analysis spectrum, resulting in low purity of the isotretinoin crystalline product and ultimately poor stability of the isotretinoin crystalline product; at the same time, through algorithm calculation, the influence of the above-mentioned factors on the stability of the isotretinoin crystalline product can be understood more concisely and accurately, and the stability of the isotretinoin crystalline product can be comprehensively improved.
[0150] F represents the influence of the characteristic peak of the isotretinoin crystalline product in the X-ray powder diffraction pattern, which represents the influence of the peak width and the diffraction angle on the characteristic peak position in the X-ray powder diffraction pattern.
[0151] The influence factor representing the unit value of the characteristic peak influence can be obtained based on the historical peak width and diffraction intensity data statistics. It represents the degree of influence of the change in the characteristic peak influence. Its value range is 0.55 to 0.85. In this example, the value is set to 0.58.
[0152] R represents the heat flow corresponding to the endothermic peak position of the isotretinoin crystalline product, and represents the thermal response value corresponding to the endothermic peak position located in the differential thermal analysis spectrum.
[0153] The influence factor of the unit value of heat flow can be obtained comprehensively based on historical heat flow data and expert opinion reports. It represents the degree of influence of heat flow changes. Its value range is 0.55 to 0.88. In this example, the value is specified as 0.56.
[0154] C represents the purity of the isotretinoin crystalline product, which refers to the purity of the isotretinoin crystalline product finally prepared.
[0155] The purity limit value of the isotretinoin crystalline product refers to the minimum purity value. In this exemplary embodiment, the purity limit value of the isotretinoin crystalline product is 99.0%.
[0156] The evaluation factor representing the preparation stability evaluation index can be obtained based on the historical stability evaluation data, and represents the evaluation degree of the change of the preparation stability evaluation index. Its value range is 0.88 to 0.99, and the value in this example is specified as 0.98.
[0157] H is the content of 5,6-epoxyisotretinoin, which refers to the impurities generated when the isotretinoin crystalline product is exposed to air.
[0158] T is the duration of the air exposure cycle, It is the impact factor corresponding to the unit value of the formation rate of 5,6-epoxyisotretinoin, which indicates the degree of stability of the influence of the formation rate of the impurity 5,6-epoxyisotretinoin. It can be obtained based on the historical formation data of the impurity 5,6-epoxyisotretinoin, and the value range is 0 to 1.
[0159] Example 6: The preparation process of the isotretinoin crystalline product was obtained according to the following steps, and a comparative example 1 was prepared. The final comparison results are shown in Table 2:
[0160] The preparation process of Example 6:
[0161] Under nitrogen protection, 10 g of crude isotretinoin was weighed into a 500 ml three-necked flask, 100 ml of ethyl acetate was added, stirring was started, the temperature was raised to 65 ° C to dissolve, the temperature was lowered to 0 ° C for crystallization for 10 hours, and the filter cake was vacuum dried at 50 ° C to obtain 8.58 g of isotretinoin A crystal form, and the mass yield of the isotretinoin crystalline product was 85.8%. When the isotretinoin crystalline product was exposed to air for 0 days, its purity was 99.89%, and the content of oxidized impurity 5,6-epoxy-isotretinoin was 0.03%; at the same time, when the isotretinoin crystalline product was exposed to air for 10 days, its purity was 99.88%, and the content of oxidized impurity 5,6-epoxy-isotretinoin was 0.04%.
[0162] Preparation process of comparative example 1:
[0163] Under nitrogen protection, 4 g of crude isotretinoin was weighed into a 500 ml three-necked flask, 120 ml of methanol was added, stirring was started, the temperature was raised to 50 ° C to dissolve, the temperature was lowered to 5 ° C for crystallization for 20 hours, and the filter cake was dried in vacuo at 40 ° C to obtain 2.95 g of isotretinoin. The mass yield of the isotretinoin crystalline product was 73.4%. When the isotretinoin crystalline product was exposed to air for 0 days, its purity was 99.68%, and the content of 5,6-epoxy-isotretinoin oxidized to impurities was 0.04%; at the same time, when the isotretinoin crystalline product was exposed to air for 10 days, its purity was 99.42%, and the content of 5,6-epoxy-isotretinoin oxidized to impurities was 0.25%.
[0164] Table 2 Comparison results of the preparation process of isotretinoin crystalline products
[0165]
[0166] Through the comparison results in Table 2, it can be obtained that the final mass yield and purity of the isotretinoin crystalline product will be different depending on the type of organic solvent, the temperature of the heating operation, the preparation process and other factors. At the same time, it can be known that the purity of the isotretinoin crystalline product is proportional to the storage time, that is, the longer the storage time, the lower the purity.
[0167] Through the comparison results of the weight of 5,6-epoxyisotretinoin in the above Table 2, it can be obtained that since the isotretinoin crystalline preparation of Example 6 and the isotretinoin crystalline preparation of Comparative Example 1 are exposed to the air at the same time, there is a large difference in the final impurity 5,6-epoxyisotretinoin content. The impurity 5,6-epoxyisotretinoin content obtained by exposing the isotretinoin crystalline preparation in Example 6 to the air is much smaller than that in Comparative Example 1, indicating that the preparation process, solvent type and other factors in this example that are different from those in the Comparative Example can improve the stability of the isotretinoin crystalline preparation, which is ultimately beneficial for application in the chemical field, so that isotretinoin has practical value.
[0168] In the embodiments, the present invention can evaluate the preparation stability of the isotretinoin crystalline product based on the purity of the isotretinoin crystalline product, the X-ray powder diffraction pattern of the isotretinoin crystalline product, and the differential thermal analysis pattern of the isotretinoin crystalline product. At the same time, the content of 5,6-epoxyisotretinoin in the isotretinoin crystalline product during the air exposure period can be used to understand the impurity content generated by the isotretinoin crystalline product prepared by the present invention when exposed to the air. The preparation process can be adjusted and managed in time according to the impurity growth rate of the isotretinoin crystalline product to improve the preparation stability of the isotretinoin crystalline product, and at the same time, it is beneficial for the isotretinoin crystalline product to show practical value in the field of chemistry.
[0169] In a specific embodiment, the present invention provides an isotretinoin crystalline product and a preparation method thereof. First, the solubility corresponding to the isotretinoin crude solution to be prepared is determined, and the dissolution of the isotretinoin crude solution can be clearly obtained. Secondly, the preparation of the isotretinoin crude solution is controlled, and the preparation process of the isotretinoin crude solution can be analyzed in detail, providing data basis for the final evaluation of the stability of the isotretinoin crystalline product.
[0170] The above contents are merely examples and explanations of the structure of the present invention. The technicians in this technical field may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the structure of the invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.
Claims
1. A method for preparing an isotretinoin crystalline product, characterized in that: include: S1. Heating and dissolving: Under nitrogen protection, weigh the initial weight of crude isotretinoin into a container, add ethyl acetate, heat to a specified temperature to dissolve, and start stirring; S2. Preparation control determination: After stirring, data processing is performed to obtain the solubility corresponding to the crude isotretinoin solution to be prepared. When the solubility corresponding to the crude isotretinoin solution to be prepared determined by the preparation control system is higher than the solubility of the solution corresponding to the set temperature, the preparation control system controls the temperature control device to reduce the crude isotretinoin solution to a preset temperature; S3. Preparation of isotretinoin crystalline product: controlling the crystallization device through the preparation control system so that the crystallization time of the isotretinoin crude solution is the preset crystallization time, controlling the filtering device so that the filtration times of the isotretinoin crude solution are the preset filtration times, and vacuum drying the obtained filter cake at a specified temperature controlled by the preparation control system to obtain an isotretinoin crystalline product; Calculated based on the weight of the crude product, the amount of ethyl acetate used is 10-20 ml / g; The preparation control system comprises: A temperature rise dissolution determination module is used to dissolve the crude isotretinoin to be prepared in ethyl acetate and perform a temperature rise operation to determine the solubility corresponding to the crude isotretinoin solution to be prepared. If the solubility corresponding to the crude isotretinoin solution to be prepared is higher than the solubility of the solution corresponding to the set temperature, the preparation control evaluation module is executed, and the crude isotretinoin solution to be prepared is recorded as an isotretinoin preparable crude solution. Otherwise, the temperature rise dissolution determination module is continued to be executed; A preparation control evaluation module is used to analyze the preparation control evaluation factors of the isotretinoin preparable crude solution by performing preparation operations on the isotretinoin preparable crude solution, and record the crystalline product in the isotretinoin preparable crude solution after the preparation operation as the isotretinoin crystalline product, and match it to obtain the purity limit value of the isotretinoin crystalline product; A stable state evaluation module is used to obtain a preparation stability evaluation index of the isotretinoin crystalline product according to the purity limit value of the isotretinoin crystalline product and to comprehensively analyze the obtained X-ray powder diffraction pattern of the isotretinoin crystalline product, the differential thermal analysis pattern of the isotretinoin crystalline product, and the 5,6-epoxyisotretinoin content of the isotretinoin crystalline product during the air exposure period, and to evaluate the preparation stability of the isotretinoin crystalline product; The isotretinoin crystalline product uses Cu target Kα radiation, takes the diffraction peak position 2θ as the characteristic parameter of the spectrum, and its powder X-ray powder diffraction pattern has characteristic peaks at 5.74±0.2, 10.45±0.2, 11.48±0.2, 11.92±0.2, 12.62±0.2, 15.94±0.2, 16.43±0.2, 16.67±0.2, 16.70±0.2, 18.07±0.2, 18.34±0.2, 19.69±0.2, 20.21±0.2, 21.75±0.27, 23.95±0.27, 24.70±0.27, 25.37±0.27, 26.97±0.27 and 27.56±0.2; The preparation control evaluation factor of the crude solution of isotretinoin can be prepared, and the formula is as follows: Wherein, τ is the preparation control evaluation factor of isotretinoin that can prepare a crude solution, β1 is the first control evaluation index of isotretinoin that can prepare a crude solution, β2 is the second control evaluation index of isotretinoin that can prepare a crude solution, β3 is the third control evaluation index of isotretinoin that can prepare a crude solution, β4 is the fourth control evaluation index of isotretinoin that can prepare a crude solution, ΔM is the mass defined yield, M is the mass yield of the isotretinoin crystalline product, and y5 is the correction value of the preparation control evaluation factor; The specific formula for the preparation stability evaluation index of the isotretinoin crystalline product is as follows: Wherein, μ represents the preparation stability evaluation index of isotretinoin crystalline product, F represents the characteristic peak influence degree of isotretinoin crystalline product in X-ray powder diffraction pattern, j1 represents the influence factor of characteristic peak influence degree corresponding to unit value, R represents the heat flow corresponding to the endothermic peak position of isotretinoin crystalline product, j2 represents the influence factor of heat flow corresponding to unit value, C represents the purity of isotretinoin crystalline product, C min represents the purity limit value of isotretinoin crystalline product, j3 represents the evaluation factor of preparation stability assessment index, H represents the 5,6-epoxyisotretinoin content, T represents the duration corresponding to the air exposure cycle, and j4 represents the influencing factor corresponding to the unit value of 5,6-epoxyisotretinoin generation rate.
2. The method for preparing the isotretinoin crystalline product according to claim 1, characterized in that: The solubility of the crude isotretinoin solution to be prepared is specifically determined by: Dissolving the crude isotretinoin to be prepared in ethyl acetate, and obtaining a volume corresponding to ethyl acetate; According to the temperature rising operation, the crude isotretinoin solution to be prepared is randomly arranged as various temperature rising collection points, and the temperature value of each temperature rising collection point at each dissolution time point is obtained. The temperature value and the set dissolution temperature reference value are comprehensively analyzed and processed through a polynomial regression model to obtain the dissolution temperature index corresponding to each dissolution time point, and the dissolution temperature index change curve of the crude isotretinoin solution to be prepared is constructed, from which the connecting straight line between the dissolution temperature index corresponding to the starting dissolution time point and the dissolution temperature index corresponding to the ending dissolution time point is located, and the slope corresponding to the connecting straight line is recorded as the dissolution temperature slope of the crude isotretinoin solution to be prepared, thereby determining the solubility corresponding to the crude isotretinoin solution to be prepared.
3. The method for preparing the isotretinoin crystalline product according to claim 1, characterized in that: The preparation control evaluation factors of the crude solution of isotretinoin can be prepared by analyzing the specific analysis process as follows: The mass of the obtained isotretinoin crystalline product is compared with the mass of the isotretinoin crude solution that can be prepared, to obtain the mass yield of the isotretinoin crystalline product; According to the mass yield of the isotretinoin crystalline product and the first control evaluation index of isotretinoin that can be prepared as a crude solution, the second control evaluation index of isotretinoin that can be prepared as a crude solution, the third control evaluation index of isotretinoin that can be prepared as a crude solution and the fourth control evaluation index of isotretinoin that can be prepared as a crude solution, the preparation control evaluation factor of isotretinoin that can be prepared as a crude solution is obtained.
4. The method for preparing the isotretinoin crystalline product according to claim 1, characterized in that: The preparation stability evaluation index of the isotretinoin crystalline product is specifically analyzed as follows: According to the X-ray powder diffraction spectrum of the isotretinoin crystalline product, the characteristic peak position number of the isotretinoin crystalline product is extracted therefrom, thereby obtaining the peak width and diffraction intensity corresponding to each characteristic peak position of the isotretinoin crystalline product; The peak width and diffraction intensity of the isotretinoin crystalline product at each characteristic peak position are processed to obtain the characteristic peak influence of the isotretinoin crystalline product in the X-ray powder diffraction pattern; According to the differential thermal analysis spectrum of the isotretinoin crystalline preparation, the heat flow corresponding to the endothermic peak position of the isotretinoin crystalline preparation is located and extracted, and the purity of the isotretinoin crystalline preparation is obtained. At the same time, the 5,6-epoxyisotretinoin content of the isotretinoin crystalline preparation during the air exposure period is comprehensively analyzed to analyze the preparation stability evaluation index of the isotretinoin crystalline preparation.
5. The method for preparing the isotretinoin crystalline product according to claim 1, characterized in that: The preparation stability of the isotretinoin crystalline product is evaluated, and the specific evaluation process is as follows: The preparation stability assessment index of the isotretinoin crystalline product is compared with the set preparation stability assessment threshold. If the preparation stability assessment index of the isotretinoin crystalline product is higher than the set preparation stability assessment threshold, preparation stability feedback is performed on the preparation stability state of the isotretinoin crystalline product. If the preparation stability assessment index of the isotretinoin crystalline product is equal to or lower than the set preparation stability assessment threshold, a preparation alarm is given to the preparation stability state of the isotretinoin crystalline product.
